StreetAlpha.app
Home › Stocks › GILD

Gilead Sciences, Inc. (GILD)

Healthcare
$166.43
▼ −0.06%
LAST CLOSE · NOV 20

Gilead is a biopharmaceutical company that develops and sells medicines for HIV, hepatitis, cancer and other diseases. It last closed at $166.43 on Nov 20, down 0.06% on the day. The next earnings report for GILD is expected around Tue, Feb 9, 2027, after the close. For the quarter ended Sep 2026, GILD reported EPS of $1.94 on revenue of $8.30B, with revenue up 6.8% from a year ago. Over its last 8 reports the stock moved an average of 4.1% the session after earnings. Over the last 12 months GILD insiders bought $0 of stock on the open market and sold $108.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is GILD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GILD.

Key Stats

Last 12 months
Results
Revenue
$31.0B
+6.5% vs a year ago
Net income
−$3.9B
−147.6% vs a year ago
EPS (diluted)
−$3.13
−148.5% vs a year ago
Free cash flow
$13.8B
44.5% margin
Valuation
Market cap
$206B
1.24B shares
P/E
–
No P/E while losing money
Price to sales
6.7
Market cap over revenue
Dividend yield
1.95%
$3.25 a share over 12 months
Balance sheet
Cash & equivalents
$6.4B
At Sep 30
Debt
$26.2B
At Sep 30
Shareholder equity
$13.0B
Buybacks
$1.4B
Last 12 months
CEODaniel O'Day
Employees17,000 (Jul 1, 2026)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $27.3B$27.3BFY2021FY2022: $27.3B$27.3BFY2022FY2023: $27.1B$27.1BFY2023FY2024: $28.8B$28.8BFY2024FY2025: $29.4B$29.4BFY2025

From GILD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 30). Last 12 months adds up the four latest quarters.

Next report
Feb 9
Estimated date · After the close
Reported EPS
$1.94
Quarter ended Sep 2026
Year ago EPS
$2.43
−20.2% on a GAAP basis
Revenue
$8.30B
+6.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $1.42Dec '24Mar 2025: $1.04Mar '25Jun 2025: $1.56Jun '25Sep 2025: $2.43Sep '25Dec 2025: $1.74Dec '25Mar 2026: $1.61Mar '26Jun 2026: -$8.45Jun '26Sep 2026: $1.94Sep '26Latest $1.94
Revenue by quarter
Dec 2024: $7.57BDec '24Mar 2025: $6.67BMar '25Jun 2025: $7.08BJun '25Sep 2025: $7.77BSep '25Dec 2025: $7.92BDec '25Mar 2026: $6.96BMar '26Jun 2026: $7.80BJun '26Sep 2026: $8.30BSep '26Latest $8.30B
How GILD moved after its last 8 reports
Average move the session after a report ±4.1%
Oct 29, 2026After the close+3.1%
Aug 4, 2026After the close−2.6%
May 7, 2026After the close−2.0%
Feb 10, 2026After the close+5.8%
Oct 30, 2025After the close+1.1%
Aug 7, 2025After the close+8.3%
Apr 24, 2025After the close−2.8%
Feb 11, 2025After the close+7.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on GILDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on GILD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on GILD

Technical Analysis

GILD · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 14% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 54). The nearest support is the Pivot S1 at $164.74, and the nearest resistance the 20 day average at $167.29.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 2.7%/day
Key levels
$176.5852 week high+6.1%
$171.80Swing high (Nov 16)+3.2%
$169.18Pivot R1+1.7%
$167.49Pivot+0.6%
$167.2920 day average+0.5%
$166.43Last close
$164.74Pivot S1−1.0%
$164.00Swing low (Nov 6)−1.5%
$157.2650 day average−5.5%
$147.67100 day average−11.3%
$142.30200 day average−14.5%
$116.8852 week low−29.8%
Indicators
RSI (14)54.42Middle of its rangeNeutral
MACD3.21Below its signal lineBearish
Stochastic26.3Middle of its rangeNeutral
ADX (14)30.2Trending up
Williams %R-80.7Oversold below −80, overbought above −20Oversold
CCI (20)3.9Oversold below −100, overbought above 100Neutral
Rate of change−0.3%Change over 10 sessionsBearish
ATR (14)$4.54Typical daily range, 2.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for GILD

What happened before

See how GILD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow GILD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How GILD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for GILDHow many large options trades hit GILD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

GILD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲1,150 buying vs 972 selling
  • ▼Held by funds -2.9 pts
  • ▲Funds holding +69
  • ▼Superinvestors: 2 added, 3 cut
  • ▼Put/call 0.30 to 1.00
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2,3592,290+3.0%
In funds' top 102616+62.5%
Held by funds87.0%89.9%−2.9 pts
New / increased228 / 922125 / 928+9.2%
Reduced / sold out831 / 141853 / 167−4.7%
Put/call ratio1.000.30+233.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GILD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

GILD Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$108.9M46 sales · 7 insiders
99% of the selling was under pre-arranged trading plans.
2025-12 sold $2.0M2026-01 sold $18.4M2026-02 sold $23.6M2026-03 sold $2.2M2026-04 sold $2.1M2026-05 sold $4.1M2026-06 sold $2.7M2026-07 sold $2.7M2026-08 sold $9.6M2026-09 sold $3.1M2026-10 sold $3.2M2026-11 sold $32.6MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Andrew D DickinsonCFOSale plan3,000$171.47$514K
Nov 16Johanna MercierChief Comm & Corp Aff OfficerSale plan28,000$170.55$4.8M
Nov 12Kelly A. KramerDirectorSale plan10,376$169.76$1.8M
Nov 6Wettan Keeley M CainEVP Gen Counsel, Legal & CompSale plan3,399$164.11$558K
Nov 5Daniel Patrick O'DayChairman & CEOSale plan112,429$175.16$19.7M
Nov 2Daniel Patrick O'DayChairman & CEOSale plan30,881$172.57$5.3M
Every insider buy and sale for GILD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See GILD insider trades →

From SEC Form 4 filings by GILD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

GILD Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$1.4B
0.7% yield
Left in program
$5.7B
2.7% of value
Shares outstanding, 12 months
−0.0%
Fewer shares
Last quarter
$504.5M
Sep 2026
Avg price paid, last quarter
$139.28
3.6M shares bought
S&P 500 rank by spending
#144 of 358
 
Spent each quarter, last 3 yearsTop bar $905.7M
Dec 2023: $183.9M, average price $77.51Mar 2024: $516.3M, average price $76.61Jun 2024: $133.2M, average price $66.37Sep 2024: $382.4M, average price $76.32Dec 2024: $397.4M, average price $91.58Mar 2025: $905.7M, average price $104.15Jun 2025: $587.2M, average price $106.10Sep 2025: $572.7M, average price $114.25Dec 2025: $292.6M, average price $119.17Mar 2026: $598.1M, average price $139.49Jun 2026: $416.3M, average price $130.59Sep 2026: $504.5M, average price $139.28
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 30, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GILD is in one of them and how their past GILD trades turned out.

GILD in the AI portfolios
Loading…

GILD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GILD in an article yet. Here's the latest on the wider market.

GILD in the news

GILD Congress Trades

All congress trades →
Trades, 12 months
5
Buys
4
80%
Sells
1
20%
People
4
Last filed Sep 4
Who traded GILD · since 2014
Latest 5 filings of 146
Ro KhannaSell (partial)
$1K – $15KTraded Aug 10, 2026Filed Sep 4, 2026
$1K – $15KTraded Mar 27, 2026Filed Jul 21, 2026
$1K – $15KTraded May 6, 2026Filed Jun 19, 2026
$1K – $15KTraded May 6, 2026Filed Jun 19, 2026
$1K – $15KTraded Jan 27, 2026Filed Feb 26, 2026
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CASell (partial)$1K – $15KAug 10, 2026Sep 4, 202625 d
Alan ArmstrongR · OKBuy$1K – $15KMar 27, 2026Jul 21, 2026116 d
Jared MoskowitzD · FLBuy$1K – $15KMay 6, 2026Jun 19, 202644 d
Jared MoskowitzD · FLBuy$1K – $15KMay 6, 2026Jun 19, 202644 d
Josh GottheimerD · NJBuy$1K – $15KJan 27, 2026Feb 26, 202630 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Gilead Sciences

Gilead is a biopharmaceutical company based in Foster City, California. It develops and sells medicines for viral diseases, including HIV and hepatitis, along with cancer treatments such as a breast cancer drug and cell therapies for certain blood cancers. Its portfolio also includes an antifungal medicine and a COVID-19 treatment. Gilead sells to hospitals, clinics and other healthcare providers, largely through wholesalers, distributors and partners.

Headquarters
Foster City, CA
Founded
1987